ERIN COLVARD: Open Payments
NPI 1508429457 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,813 in 103 payments from 16 companies in 2025. Trend: 2023 $2,159 · 2024 $2,265 · 2025 $1,813
Food & beverage: $1,701Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $278 |
| Lundbeck LLC | 12 | $277 |
| Otsuka America Pharmaceutical, Inc. | 14 | $254 |
| ABBVIE INC. | 13 | $200 |
| Neurocrine BioSciences, Inc. | 12 | $184 |
| Teva Pharmaceuticals USA, Inc. | 6 | $167 |
| Vanda Pharmaceuticals Inc. | 5 | $117 |
| Axsome Therapeutics, Inc. | 6 | $107 |
| E.R. Squibb & Sons, L.L.C. | 4 | $76 |
| Alkermes, Inc. | 2 | $35 |
Products named: REXULTI, CAPLYTA, VRAYLAR, INGREZZA, FANAPT, Auvelity, COBENFY, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
